Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autoimmune Hepatitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    52 result(s) found for: Autoimmune Hepatitis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-003990-23 Sponsor Protocol Number: BP42698 Start Date*: 2021-06-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWING STEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS
    Medical condition: Autoimmune Hepatitis (AIH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10003827 Autoimmune hepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Completed) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001555-32 Sponsor Protocol Number: CVAY736B2201 Start Date*: 2017-11-13
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete ...
    Medical condition: Autoimmune Hepatitis (AIH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10003827 Autoimmune hepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003311-19 Sponsor Protocol Number: AIH-MAB Start Date*: 2018-01-09
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximab AIH-MAB
    Medical condition: Autoimmune Hepatitis (AIH); rare inflammatory liver disease associated with elevated transaminases, elevated Immunoglobulin G, the presence of autoantibodies and interface hepatitis in liver histol...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001377-28 Sponsor Protocol Number: 27577 Start Date*: 2008-06-11
    Sponsor Name:Merck Serono International S.A.
    Full Title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of...
    Medical condition: Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061664 Autoimmune disorder LLT
    9.1 10025139 Lupus erythematosus systemic LLT
    9.1 10047888 Wegener's granulomatosis LLT
    9.1 10002817 Antiphospholipid syndrome LLT
    9.1 10040767 Sjogren's syndrome LLT
    9.1 10039073 Rheumatoid arthritis LLT
    9.1 10028245 Multiple sclerosis LLT
    9.1 10045228 Type I diabetes mellitus LLT
    9.1 10011401 Crohn's disease LLT
    9.1 10009900 Colitis ulcerative LLT
    9.1 10003827 Autoimmune hepatitis LLT
    9.1 10049046 Autoimmune thyroiditis LLT
    9.1 10003822 Autoimmune haemolytic anaemia NOS LLT
    9.1 10034697 Pernicious anemia LLT
    9.1 10028417 Myasthenia gravis LLT
    9.1 10018620 Goodpasture's syndrome LLT
    9.1 10018766 Guillain Barre syndrome LLT
    9.1 10043554 Thrombocytopenia LLT
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001282-28 Sponsor Protocol Number: MB0001 Start Date*: 2008-09-23
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Influenza, pneumococcal and hepatitis B vaccination in patients with rheumatic autoimmune diseases treated with immunosuppressive therapy
    Medical condition: Rheumatic autoimmune diseases including rheumatoid arthritis and poly or dermatomyositis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001038-91 Sponsor Protocol Number: NL57115 Start Date*: 2016-11-18
    Sponsor Name:Leiden university medical centre
    Full Title: A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitis
    Medical condition: Autoimmune hepatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019633-10 Sponsor Protocol Number: DV2-HBV-18 Start Date*: 2010-11-18
    Sponsor Name:Dynavax Technologies Corporation
    Full Title: An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Engerix-B® and Fendrix® in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vacc...
    Medical condition: Prevention of hepatitis B virus (HBV) infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000358-38 Sponsor Protocol Number: P04755 Start Date*: 2006-05-31
    Sponsor Name:Klinikum der J. W. Goethe-Universität Frankfurt - Medizinische Klinik I
    Full Title: Individually adapted therapy duration from 24 to 72 weeks for the treatment of patients with a chronic hepatitis C genotype 1 infection with Peginterferon alfa-2b plus Ribavirin in dependence of th...
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021963-34 Sponsor Protocol Number: 2125-202 Start Date*: 2010-11-03
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who were Nonresponders to Pegylated-Interferon plus ...
    Medical condition: This is a Phase 2, randomized, double-blind, comparator-controlled study of IMO-2125 in hepatitis C-infected patients who were previously nonresponders to standard treatment (pegylated-interferon p...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008912 Chronic hepatitis C LLT
    Population Age: Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004657-11 Sponsor Protocol Number: VI-Plt-01 Start Date*: 2012-03-30
    Sponsor Name:FONDAZIONE PROGETTO EMATOLOGIA
    Full Title: Open label multicenter study of Eltrombopag for the treatment of Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs)
    Medical condition: Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10050245 Autoimmune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006651-39 Sponsor Protocol Number: 111103 Start Date*: 2008-12-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscular...
    Medical condition: No medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015877-11 Sponsor Protocol Number: DV2-HBV-17 Start Date*: 2010-07-09
    Sponsor Name:Dynavax Technologies Corporation
    Full Title: An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) among Adults (18 to 75 Years of Age) with Chronic Kidney Disease (CKD)
    Medical condition: Prevention of hepatitis B virus (HBV) infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003381-14 Sponsor Protocol Number: AIHBUDPRED1.0 Start Date*: 2020-02-19
    Sponsor Name:Umeå University Hospital
    Full Title: Budesonide versus Prednisolone as Primary Treatment for Autoimmune Hepatitis: An Open-label, Randomized, Prospective Multicenter 12-month Clinical Trial Evaluating Effect and Side-Effects.
    Medical condition: Autoimmune hepatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000859-10 Sponsor Protocol Number: ANRS HC 20 Start Date*: 2009-04-10
    Sponsor Name:ANRS
    Full Title: Etude pilote, multicentrique, évaluant l’efficacité d’un traitement anti VHC optimisé (induction par 360µg/S de PegIFN-alpha 2a + 18mg/kg/j de RBV pendant 6 mois puis en fonction de la réponse viro...
    Medical condition: Cet essai vise à étudier la réponse à un re-traitement optimisé de l’hépatite C chez des patients co-infectés VIH-VHC (génotype 1 et 4), non répondeurs aux premiers traitements pour le VHC.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10001509 AIDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003420-33 Sponsor Protocol Number: NL78216 Start Date*: 2021-12-13
    Sponsor Name:Leiden University Medical Center
    Full Title: Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first line therapy: a Randomized trial (TAILOR study)
    Medical condition: Autoimmune hepatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003766-26 Sponsor Protocol Number: 25-12-59 Start Date*: 2009-10-12
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: The effects of purified n-3 fatty acids on serum biomarkers and cardiovascular risk markers in a randomized placebo controlled trial in patients with non alcoholic fatty liver disease
    Medical condition: Non alcoholic fatty liver disease (NAFLD). This fatty liver disease may progress to a chronic condition that sometimes deteriorates further to cirrhosis and even liver carcinoma. To date there is n...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000454-18 Sponsor Protocol Number: 110058 Start Date*: 2017-07-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II randomized, observer blind, multicenter study of GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella-varicella vaccine (MMRV) versus ProQuad, according to a one dose schedu...
    Medical condition: Healthy volunteers (Use of the candidate MMRV vaccine for immunization of healthy children 12 - 14 months of age against measles, mumps, rubella and varicella).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003146-36 Sponsor Protocol Number: RIAlta-1 Start Date*: 2023-11-15
    Sponsor Name:Vall d'Hebron Research Institute (VHIR)
    Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis
    Medical condition: Pulmonary and extrapulmonary tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002368-18 Sponsor Protocol Number: HEPB-VAC-01 Start Date*: 2018-07-25
    Sponsor Name:FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
    Full Title: Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with inc...
    Medical condition: 1. Autoinmune rheumatic diseases undertreated by rituximab or infliximab. 2. breast and lung cancer undertreated by chemotherapy 3. HIV 4. Haematopoietic progenitor cell transplantation (TCPH).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058467 Lung neoplasm malignant PT
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    20.0 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002488-91 Sponsor Protocol Number: MO39874 Start Date*: 2019-11-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NAB-PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PD-L1-POSITIVE TRIPLE-NEGATI...
    Medical condition: Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Ongoing) SI (Ongoing) FR (Ongoing) HU (Ongoing) SK (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA